11:05 AM EST - Oncolytics Biotech Inc : Announced it has submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX with and without atezolizumab in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma. This amendment will be reviewed by the Paul Ehrlich Institute for approval before patient enrollment can begin. The cohort, the fifth of the GOBLET gastrointestinal cancer study, is being supported by the US$5 million Therapeutic Accelerator Award from the Pancreatic Cancer Action Network, an innovative program established to accelerate the development of new treatments for pancreatic cancer. Evaluation of this novel treatment approach will complement Oncolytics' ongoing development of pelareorep, atezolizumab, gemcitabine, and nab-paclitaxel in PDAC, which is expected to advance to a registrational study later this year. Oncolytics Biotech Inc
shares T.ONC are trading up $0.09 at $1.33.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=5188058229728308
